Table 7 Cox proportional hazard regressions for the estimation of adjusted HRs. Follow-up duration of samples ≧ 6 months

Hashimoto’s thyroiditis

6.58 (5.02–8.61)

5.26 (3.95–7.01)

4.13 (3.02–5.65)

3.54 (2.33–5.36)

 No Hashimoto’s thyroiditis

Ref.

Ref.

Ref.

Ref.

 Hashimoto’s thyroiditis, no hyperthyroidism, and no hypothyroidism

6.91 (4.67–10.25)

5.58 (3.72–8.36)

4.10 (2.65–6.36)

3.22 (1.87–5.53)

 Hashimoto’s thyroiditis and hyperthyroidism only

3.85 (1.71–8.65)

3.11 (1.37–7.05)

2.97 (1.30–6.75)

1.98 (0.78–5.05)

 Hashimoto’s thyroiditis and hypothyroidism only

7.21 (4.86–10.68)

5.79 (3.86–8.68)

4.65 (3.03–7.14)

4.25 (2.57–7.03)

 Hashimoto’s thyroiditis and hyperthyroidism and hypothyroidism

6.99 (3.45–14.15)

5.26 (2.57–10.76)

3.94 (1.87–8.33)

4.33 (2.01–9.32)

Sex—male

0.20 (0.10–0.41)

0.19 (0.10–0.39)

0.21 (0.11–0.43)

0.20 (0.10–0.40)

0.21 (0.11–0.43)

Age

1.00 (0.99–1.01)

0.99 (0.99–1.001)

0.99 (0.98–0.99)

0.99 (0.99–1.001)

0.99 (0.98–0.99)

 Urban

Ref.

Ref.

Ref.

Ref.

Ref.

 Suburban

0.98 (0.76–1.28)

1.05 (0.80–1.37)

1.03 (0.79–1.35)

1.05 (0.80–1.37)

1.04 (0.79–1.35)

 Rural

1.05 (0.76–1.45)

1.14 (0.82–1.58)

1.10 (0.79–1.53)

1.14 (0.82–1.58)

1.10 (0.79–1.53)

Low income (≤ median 21,000 NTD/month)

1.06 (0.84–1.34)

1.04 (0.82–1.31)

1.02 (0.80–1.29)

1.04 (0.82–1.31)

1.01 (0.80–1.28)

 Times of visiting the outpatient department

1.06 (1.05–1.08)

0.99 (0.96–1.02)

0.97 (0.94–1.01)

0.99 (0.96–1.02)

0.97 (0.94–1.01)

  0 days

Ref.

Ref.

Ref.

Ref.

Ref.

  1–6 days

1.72 (0.77–3.86)

1.09 (0.48–2.48)

0.93 (0.40–2.17)

1.11 (0.49–2.51)

0.95 (0.40–2.22)

  ≥ 7 days

4.79 (2.37–9.67)

2.11 (1.01–4.41)

1.90 (0.88–4.09)

2.10 (1.004–4.41)

1.90 (0.88–4.08)

 Times of visiting the outpatient department

1.04 (1.03–1.04)

1.03 (1.01–1.04)

1.03 (1.01–1.04)

1.03 (1.01–1.04)

1.03 (1.01–1.04)

  0 days

Ref.

Ref.

Ref.

Ref.

Ref.

  1–6 days

3.35 (2.24–5.03)

2.51 (1.66–3.80)

2.05 (1.33–3.17)

2.55 (1.69–3.85)

2.06 (1.33–3.19)

  ≥ 7 days

7.08 (4.72–10.61)

4.63 (2.99–7.19)

3.46 (2.17–5.50)

4.66 (3.00–7.23)

3.47 (2.18–5.53)

  RA

18.76 (11.16–31.55)

3.37 (1.77–6.42)

3.34 (1.75–6.38)

  SS

42.89 (28.24–65.16)

7.49 (4.33–12.96)

7.45 (4.28–12.94)

  SSc

120.88 (38.75–377.04)

3.98 (1.08–14.59)

4.12 (1.10–15.42)

  Vasculitis

98.63 (36.76–264.64)

6.66 (2.11–21.07)

6.33 (1.98–20.28)

  Hypertension

1.35 (0.96–1.89)

1.42 (0.94–2.14)

1.41 (0.94–2.13)

  Diabetes mellitus

0.71 (0.38–1.33)

0.53 (0.27–1.05)

0.54 (0.27–1.05)

  Hyperlipidemia

1.08 (0.62–1.88)

0.83 (0.46–1.51)

0.82 (0.45–1.50)

  Coronary artery disease

1.28 (0.63–2.58)

0.83 (0.39–1.78)

0.83 (0.39–1.78)

  Osteoporosis

5.20 (2.99–9.07)

2.97 (1.62–5.42)

2.95 (1.62–5.39)

  Cerebral vascular accident

1.62 (0.72–3.63)

1.04 (0.44–2.47)

1.03 (0.44–2.44)

  COPD/asthma

2.00 (1.12–3.56)

1.25 (0.68–2.33)

1.24 (0.67–2.32)

  Chronic kidney disease

1.86 (0.46–7.48)

1.47 (0.36–6.05)

1.45 (0.35–5.98)

  Chronic liver diseases

3.35 (2.08–5.40)

2.34 (1.41–3.91)

2.32 (1.39–3.87)

  Pancreatitis

4.53 (0.64–32.28)

1.13 (0.15–8.80)

1.14 (0.15–8.91)

  Affective psychosis

1.42 (0.35–5.69)

0.52 (0.11–2.46)

0.53 (0.11–2.47)

  Ankylosing spondylitis

5.11 (0.72–36.31)

0.76 (0.08–7.38)

0.79 (0.08–7.57)

  IBD

0.00 (0.00–1.05E148)

0.00 (0.00–2.28E174)

0.00 (0.00–1.49E174)

  HIV infection

0.00 (0.00–2.85E155)

0.00 (0.00–9.99E999)

0.00 (0.00–9.99E999)

  AIHA

0.02 (0.00–2.33E144)

0.00 (0.00–9.99E999)

0.00 (0.00–9.99E999)

  ITP

24.38 (3.43–173.51)

8.72 (1.19–63.99)

8.79 (1.19–64.67)